consumers or clinicians intend to choose a supplement that can produce SFN according to their dosage, and compare it with the supplements used in peer-reviewed public clinical trials. Until recently, there were great difficulties in this respect, because the "extracts" of sprouts and seeds were usually labeled as "glucoraphanin", which is a descriptive commercial name and refers to "glucoraphanin". The metabolism of intestinal flora will lead to the transformation from GRN to SFN. However, the reaction efficiency is low, "about 1% to 4%".
Standardize label disclosure to eliminate inconsistency and ambiguity, which will greatly help clinicians and consumers to determine the appropriate daily dose needed to match the dose used in clinical trials.
references:
[1] C.A. Houghton, R.G. Fassett, and J.S. Coombes, "Sulforaphane: translational research from laboratory bench to clinic, ” Nutrition Reviews, vol. 71, no. 11, pp. 79–726, 213.
[2] J. W. Fahey, S. L. Wehage, W. D. Holtzclaw et al., “Protection of humans by plant glucosinolates: effiffifficiency of conversion of glucosinolates to isothiocyanates by the gastrointestinal microflflor a,” Cancer Prevention Research, vol. 5, no. 4, pp. 63–611, 212.